Ángel Luis Rodríguez de la Cuerda, longtime secretary general of AESEG, the trade association of generic producers in Spain, comments on the key role played by generic medicines during the COVID-19 pandemic and the importance of new investment to increase Spain’s generic production capabilities. In addition, he outlines specific policy changes that could expand patient access and create significant savings for the public health system.
Since the beginning of the pandemic, generic drug laboratories have been working at full capacity to guarantee the production and supply of drugs to all hospitals and pharmacies in the country
